LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Kodu・Aktsiate loetelu・Kura Oncology Inc

Kura Oncology Inc

Avatud

SektorTervishoid

8.81 1.85

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.58

Max

8.99

Põhinäitajad
By Trading Economics
Sissetulek	7.7M -73M
Müük	929K 18M
Aktsiakasum	-0.828
Kasumimarginaal	-401.495
Töötajad	260
EBITDA	7.4M -78M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+228.39% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-42M 802M
Eelmine avamishind	6.96
Eelmine sulgemishind	8.81

Uudiste sentiment

By Acuity

100%

320 / 344 Pingereas Healthcare

Kura Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. juuni 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8. juuni 2026, 15:41 UTC

Suurimad hinnamuutused turgudel

American Battery Shares Jump on Energy Department Victory

8. juuni 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8. juuni 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8. juuni 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8. juuni 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8. juuni 2026, 21:57 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8. juuni 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Agrees to Buy m3ter

8. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8. juuni 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8. juuni 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8. juuni 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8. juuni 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8. juuni 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8. juuni 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8. juuni 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8. juuni 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. juuni 2026, 16:55 UTC

Omandamised, ülevõtmised, äriostud

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8. juuni 2026, 16:54 UTC

Omandamised, ülevõtmised, äriostud

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8. juuni 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8. juuni 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8. juuni 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8. juuni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. juuni 2026, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Orange Bought Stake From Lorca

8. juuni 2026, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8. juuni 2026, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Orange Acquires 100% Ownership of MasOrange

8. juuni 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8. juuni 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8. juuni 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8. juuni 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Kura Oncology Inc Prognoos

Hinnasiht

By TipRanks

228.39% tõus

12 kuu keskmine prognoos

Keskmine 28.11 USD 228.39%

Kõrge 40 USD

Madal 15 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Kura Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Kura Oncology Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

320 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.